Literature DB >> 24566768

Role of the local bone renin‑angiotensin system in steroid‑induced osteonecrosis in rabbits.

Yongtao Zhang1, Kunzheng Wang1, Qichun Song1, Ruiyu Liu1, Wenchen Ji2, Le Ji1, Chunsheng Wang1.   

Abstract

The specific pathogenesis of steroid‑induced osteonecrosis (ON) is yet to be elucidated and until recently effective prophylactic therapies have not been available. The local renin‑angiotensin system (RAS) exists in the bone and has an important role in local bone regulation. However, to the best of our knowledge, the interrelation between local bone RAS and steroid‑induced ON is yet to be investigated. In the present study, 45 rabbits were injected with a single intramuscular dose of 20 mg/kg methylprednisolone acetate (MPA) and were sacrificed 1 (group A), 2 (group B) and 3 (group C) weeks subsequent to MPA administration (n=15 per group). Ten rabbits were used as a control group (group N). The presence or absence of ON in the bilateral femoral heads was examined histopathologically. The mRNA and protein expression of components of the RAS, including angiotensin II (Ang II), angiotensin converting enzyme (ACE) and Ang II type 1 (AT1) and Ang II type 2 (AT2) receptors, were detected in the bone. Significant changes in Ang II, ACE, and AT1 and AT2 receptor expression were observed in the bone of the rabbits in the different groups. Moreover, the expression of Ang II and ACE was highest one week subsequent to administration of the glucocorticoid methylprednisolone and the expression of the AT1 and AT2 receptors was highest two weeks following methylprednisolone administration. ON occurs most significantly at three weeks following the administration of MPA in this animal model, thus the changes in Ang II, ACE and AT1 and AT2 receptor expression preceded this. The present study found that ON was strongly associated with the activation of the local bone RAS in rabbits.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24566768     DOI: 10.3892/mmr.2014.1978

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  6 in total

1.  Renin inhibitor aliskiren exerts beneficial effect on trabecular bone by regulating skeletal renin-angiotensin system and kallikrein-kinin system in ovariectomized mice.

Authors:  Y Zhang; L Wang; Y Song; X Zhao; M S Wong; W Zhang
Journal:  Osteoporos Int       Date:  2015-10-06       Impact factor: 4.507

2.  Angiotensin (1-7) ameliorates the structural and biochemical alterations of ovariectomy-induced osteoporosis in rats via activation of ACE-2/Mas receptor axis.

Authors:  Hatem M Abuohashish; Mohammed M Ahmed; Dina Sabry; Mahmoud M Khattab; Salim S Al-Rejaie
Journal:  Sci Rep       Date:  2017-05-23       Impact factor: 4.379

3.  Research in the precaution of recombinant human erythropoietin to steroid-induced osteonecrosis of the rat femoral head.

Authors:  Lu-Yong Jiang; Xiao Yu; Qing-Jiang Pang
Journal:  J Int Med Res       Date:  2017-06-12       Impact factor: 1.671

4.  Telmisartan Prevents Alveolar Bone Loss by Decreasing the Expression of Osteoclasts Markers in Hypertensive Rats With Periodontal Disease.

Authors:  Victor Gustavo Balera Brito; Mariana Sousa Patrocinio; Maria Carolina Linjardi de Sousa; Ayná Emanuelli Alves Barreto; Sabrina Cruz Tfaile Frasnelli; Vanessa Soares Lara; Carlos Ferreira Santos; Sandra Helena Penha Oliveira
Journal:  Front Pharmacol       Date:  2020-11-11       Impact factor: 5.810

5.  Effects of the Local Bone Renin-Angiotensin System on Titanium-Particle-Induced Periprosthetic Osteolysis.

Authors:  Zhiping Zhao; Changyao Wang; Yingxing Xu; Xiangyu Wang; Bin Jia; Tengbo Yu; Yingzhen Wang; Yongtao Zhang
Journal:  Front Pharmacol       Date:  2021-06-24       Impact factor: 5.810

6.  Inhibition on angiotensin-converting enzyme exerts beneficial effects on trabecular bone in orchidectomized mice.

Authors:  Xiang-Fan Chen; Xiao-Li Li; Jin-Xin Liu; Jing Xu; Yan-Yan Zhao; Min Yang; Yan Zhang
Journal:  Pharmacol Rep       Date:  2018-02-07       Impact factor: 3.024

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.